News Related to CAR-NK Cell Therapy

Related coverage linked through entity extraction aliases.

Donor Cord Blood Composition May Influence CAR NK Cell Therapy Outcomes

Jul 30, 2026

A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.

CAR-NK and CAR-NKT Cell Therapies Show Promise Across Multiple Cancer Types

May 22, 2026

A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.